ATE367164T1 - Verwendung von 4-thiouridin oder isomaltitol zur behandlung von entzündungen und/oder hämostasis - Google Patents

Verwendung von 4-thiouridin oder isomaltitol zur behandlung von entzündungen und/oder hämostasis

Info

Publication number
ATE367164T1
ATE367164T1 AT00937418T AT00937418T ATE367164T1 AT E367164 T1 ATE367164 T1 AT E367164T1 AT 00937418 T AT00937418 T AT 00937418T AT 00937418 T AT00937418 T AT 00937418T AT E367164 T1 ATE367164 T1 AT E367164T1
Authority
AT
Austria
Prior art keywords
hemostasis
isomaltitol
thiouridine
treat inflammation
uridine
Prior art date
Application number
AT00937418T
Other languages
English (en)
Inventor
Srinivas Uppugunduri
Original Assignee
Srinivas Uppugunduri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Srinivas Uppugunduri filed Critical Srinivas Uppugunduri
Application granted granted Critical
Publication of ATE367164T1 publication Critical patent/ATE367164T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00937418T 1999-05-05 2000-05-02 Verwendung von 4-thiouridin oder isomaltitol zur behandlung von entzündungen und/oder hämostasis ATE367164T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9901615A SE521031C2 (sv) 1999-05-05 1999-05-05 Nya specifika inhibitorer av akut och kronisk inflammation

Publications (1)

Publication Number Publication Date
ATE367164T1 true ATE367164T1 (de) 2007-08-15

Family

ID=20415466

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00937418T ATE367164T1 (de) 1999-05-05 2000-05-02 Verwendung von 4-thiouridin oder isomaltitol zur behandlung von entzündungen und/oder hämostasis

Country Status (10)

Country Link
US (2) US20020061863A1 (de)
EP (2) EP1181021B1 (de)
JP (1) JP2002544165A (de)
AT (1) ATE367164T1 (de)
AU (1) AU776520B2 (de)
BR (1) BR0010283A (de)
CA (1) CA2373052A1 (de)
DE (1) DE60035583T2 (de)
SE (1) SE521031C2 (de)
WO (1) WO2000067759A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE529064C2 (sv) * 2005-01-03 2007-04-24 Selectica Pharmaceuticals Ab Topiska kompositioner
US8410125B2 (en) 2007-11-05 2013-04-02 Yagna Limited Sulfonated precursors of thymidine for the treatment of epithelial hyperplasias
WO2019112383A1 (ko) * 2017-12-08 2019-06-13 윤주석 금속 미네랄 디아미네이트 및 이의 제조방법
CN114469981A (zh) * 2021-12-16 2022-05-13 中国科学院动物研究所 尿苷在促进组织器官再生或治疗和/或预防和/或缓解和/或改善组织器官损伤中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2217628C2 (de) * 1972-04-12 1974-06-06 Sueddeutsche Zucker Ag Verfahren zur Herstellung von alpha-D-Glucopyranosido eckige Klammer auf 1-6 eckige Klammer zu sorbit (Isomaltit)
DE2307251C2 (de) * 1973-02-14 1984-03-29 Süddeutsche Zucker AG, 6800 Mannheim Arzneimittel zur Behandlung von chronischer Obstipation und Leberschäden
DE3883374T2 (de) 1987-10-28 1993-12-09 Pro Neuron Inc Acylatiertes uridin und cytidin und deren verwendungen.
US5691320A (en) * 1987-10-28 1997-11-25 Pro-Neuron, Inc. Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
US6329350B1 (en) * 1987-10-28 2001-12-11 Pro-Neuron, Inc. Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
MX9203459A (es) * 1988-11-15 1992-08-01 Merrell Pharma Inc Nuevos derivados de 2'-halometilideno, 2'-etenilideno y 2'-etinilcitidina, uridina y guanosina.
US5607925A (en) * 1988-11-15 1997-03-04 Merrell Pharmaceuticals Inc. Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides
JP2529605B2 (ja) 1989-10-23 1996-08-28 株式会社大塚製薬工場 免疫賦活剤
IT1241984B (it) * 1990-06-13 1994-02-02 Polifarma Spa Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete
DE69232798T2 (de) * 1991-08-02 2003-07-24 Denise L Faustman Diagnose und behandlung von autoimmunkrankheiten
US5229415A (en) 1992-03-24 1993-07-20 Merck & Co., Inc. Alkylthio alkyl avermectins are active antiparasitic agents
US5646182A (en) * 1992-06-15 1997-07-08 Burzynski; Stanislaw R. Methods for treating autoimmune diseases
EP0679160B1 (de) * 1992-12-08 2004-11-17 Wellstat Therapeutics Corporation Pyrimidinnukleotid-vorläufer zur behandlung entzündlicher hepatitis
WO1994026280A1 (fr) * 1993-05-19 1994-11-24 Korea Green Cross Corporation Remede contre l'arthrite contenant de l'uridine comme ingredient actif
US5567689A (en) * 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5852000A (en) * 1993-08-25 1998-12-22 Otsuka Pharmaceutical Factory, Inc. Cardiac rehabilitation agent
AU712679B2 (en) * 1994-07-01 1999-11-11 Pro-Neuron, Inc. Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
US5753625A (en) * 1995-05-12 1998-05-19 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease
US5962459A (en) * 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
SE9701219D0 (sv) * 1997-04-04 1997-04-04 Astra Pharma Prod New compounds
CA2297491A1 (en) * 1997-07-22 1999-02-04 Novimmune S.A. Methods for diagnosis and therapy of autoimmune disease, such as insulin dependent diabetes mellitus, involving retroviral superantigens
US20020006913A1 (en) * 1997-11-04 2002-01-17 Von Borstel Reid W. Antimutagenic compositions for treatment and prevention of photodamage to skin
US6673606B1 (en) * 2000-04-12 2004-01-06 The Children's Hospital Of Philadelphia Therapeutic uses for mesenchymal stromal cells

Also Published As

Publication number Publication date
BR0010283A (pt) 2003-07-29
US20050090467A1 (en) 2005-04-28
DE60035583T2 (de) 2008-04-17
EP1790348A2 (de) 2007-05-30
EP1181021A1 (de) 2002-02-27
EP1181021B1 (de) 2007-07-18
SE521031C2 (sv) 2003-09-23
JP2002544165A (ja) 2002-12-24
WO2000067759A1 (en) 2000-11-16
SE9901615D0 (sv) 1999-05-05
US20020061863A1 (en) 2002-05-23
DE60035583D1 (de) 2007-08-30
CA2373052A1 (en) 2000-11-16
AU776520B2 (en) 2004-09-16
EP1790348A3 (de) 2007-06-13
US7687476B2 (en) 2010-03-30
SE9901615L (sv) 2000-12-15
AU5259200A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
TR200000059T2 (tr) Piridin türevleri
EP1549767A4 (de) Modulation der expression von forkhead-box o1a
ATE457998T1 (de) Abgeschwächte mikroorganismen für die behandlung von infektionen
NO983688L (no) Serin-protease-inhibitorer
DE60235545D1 (de) Verfahren zur behandlung von nagelpilz und anderen mikrobiellen und mykotischen erkrankungen und dafür geeignete zusammensetzungen
TR200103634T2 (tr) Bitkilerde flavonoidlerin ve fenolik maddelerin miktarını arttırma yöntemi.
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
DE69825128D1 (de) Verwendung von azithromycin zur topischen behandlung von augeninfektionen
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
PT1537274E (pt) Tratamento enzimatico de feltros de prensa
ATE402924T1 (de) Pyridiniumsalze und deren verwendung
DE60035583D1 (de) Verwendung von 4-Thiouridin oder Isomaltitol zur Behandlung von Entzündungen und/oder Hämostasis
DE69931784D1 (de) Chemotaxis hemmendes protein von staphylococcus aureus (chips) und dessen verwendung
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60008562D1 (de) Hopfensäuren zur hemmung von staphylococcus aureus
ATE420636T1 (de) Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
EP1056458A4 (de) Methoden zur behandlung von schmerzen, einscliesslich chronischen und frauenspezifischen schmerzen
WO2004014316A3 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
ATE453386T1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE278401T1 (de) Verwendung von riluzol zur behandlung von akustischen traumazuständen
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE340182T1 (de) Sucroseoctasulphat silber saltz
DE69716056D1 (de) Acylurea-verbindungen zur behandlung von coccidioidomycosis bei warmblütigen tieren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties